‘We are not good at translating lab science into new medicines for patients’ – 20 January 2020

The discovery of “pioneer medicines” (i.e. those acting via novel molecular targets) has proven to be an immensely complex, long term, expensive and high risk endeavour. Despite formidable investments by the pharmaceutical industry and public/ charitable funders, over the past few decades in both infrastructure and technology, the success rates have remained low. During his presentation,Continue reading “‘We are not good at translating lab science into new medicines for patients’ – 20 January 2020”